(DPB) is a distinct clinicopathologic entity, which is characterized by chronic recurrent sinopulmonary infection and inflammation. We describe 3 patients with rheumatoid arthritis (RA) associated with DPB and consider that DPB is one of the bronchopulmonarymanifestations associated with RA.
Introduction
Diffuse panbronchiolitis (DPB) is a distinct clinicopathologic entity (1, 2), which is characterized by 1) symptoms: chronic cough with sputum and dyspnea on exertion; 2) physical signs: rales and rhonchi; 3) chest X-ray film: diffusely disseminated fine nodular shadows ; 4) pulmonary function test and arterial blood gas analysis:
forced expiratory volume % in one second (FEVL0%) <70%, partial pressure of oxygen (PaO2) <80 mmHg; 5) cold hemagglutinin (CHA) titer elevation; 6) association with or past history of chronic paranasal sinusitis; 7) pathological findings: respiratory bronchiolitis and peribronchiolitis. Over 1 ,000 cases of definite or probable DPB have been reported exclusively in Japan, and the reason for such a high incidence compared with Western countries is considered to be the strong correlation between DPB and human leukocyte antigen (HLA) B54, which exists only in Japanese, Chinese and Korean populations (3). We describe 3 patients with rheumatoid arthritis (RA) who developed DPB and discuss the clinical characteristics of DPB in these patients.
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Case Reports Case1
A 47-year-old woman with a 5-year history of RA complained of a progressively worsening cough and sputum production in April 1996. Since adolescence she had suffered from chronic parasinusitis, for which she underwent surgical treatment when she was 16 years old. She developed respiratory symptoms about 6 months after the onset ofRA. Due to severe RA disease activity, she took methotrexate (MTX) orally (5-6.25 mg/week) since April 1995, with slight improvement in her arthralgia, but her C-reactive protein (CRP) level remained high at 6-7 mg/dl. She had no history of smoking, and her late f ather had also suffered from RA with a productive cough. 2,660 ml (95.7% of the predicted value), 1,910 ml and 76.6 mmHg, respectively.
The productive cough and nasal discharge both decreased markedly, whereas the arthralgia severity was unchanged. The patient refused to undergo bronchoalveolar lavage (BAL), transbronchial lung biopsy (TBLB) or open lung biopsy.
Case2
A 52-year-old womanwith RA was admitted to our hospital in June 1996, complaining of exertional cough with sputum production. RA was diagnosed in 1985 and she had taken nonsteroidal antiinflammatory drugs (NSAIDs) since then and she took bucillamine from 1992 until 1994. She had suffered from parasinusitis since 1 3 years of age; she underwent surgery for breast cancer (Stage I) in October 1995, and received radiation therapy in November 1 995. As chest roentgenography revealed a ground glass opacity of the right upper lung field in the radiation area during radiation therapy and she developed a cough, oral prednisolone (PSL, 40 mg/day) was started for suspected radiation pneumonitis. The abnormal shadow disap- bilateral knee joints. There were no abnormal findings in the eyes, skin, abdomen, or upon neurological examination. Laboratory blood tests revealed an ESR of 1 10 mm/h, a CRP level of 1.7 mg/dl, aWBC countof8,900/jil and aHb level of ll.6 mg/ dl. The RF (435.2 IU/ml) and CHA titer (1:1,024) levels were high. Chest roentgenography showed diffuse fine nodular shadows in both lungs, particularly in the lower fields. Chest CT showed small nodular shadows and bronchiectasis. Pulmonary function tests revealed a VC of 1 ,550 ml (63.6% of the predicted value) and a FEVL0 of 820 ml (52.9% of the forced vital capacity). Arterial blood gas analysis while breathing room air revealed a PaO2 of61.7 mmHg, PaCO2 of38.4 mmHg and pH of 7.47. HLA typing was not done and she refused to undergo BAL, TBLB or open lung biopsy. Exacerbation of DPB was suspected, and intravenous cefpimizole sodium (2 g/day) and erythromycin (600 mg/day) was administered. Her respiratory symptoms gradually improved and she was discharged in December 1988. Although she had been prescribed erythromycin (400-600 mg/day) after discharge, she often suffered from bacterial pneumonia and died in 1989 of respiratory failure. Autopsy could not be performed.
Discussion
Clinically, all of the present 3 RA patients were considered to have DPB, according to the diagnostic criteria (1, 2). That is, they presented with appropriate clinical symptoms, including chronic cough with sputum production and dyspnea with crackles on ausculation, diffuse fine nodular shadows in both lungs, marked CHA titer elevation, hypoxia and the presence of chronic paranasal sinusitis (Table 1) . Bronchiolitis obliterans (B O) and bronchiolitis obliterans organizing pneumonia (B OOP) have also been reported as bronchiolar lesions ofRA (4, 5). BO presents as rapid onset of dyspnea, a normal or hyperinflated chest X-ray picture, and obstructive impairment of pulmonary function. The incidence ofBO associated with RA seems to be very low in comparison with that of DPB-like pulmonary manifestations (6). On the other hand, BOOP is a relatively common complication of RA characterized by wandering, patchy, ground-glass infiltrates on chest X-ray, restrictive impairment of pulmonary function, and a good response to steroid therapy. These conditions and other bronchopulmonary complications of RA including chronic bronchitis, bronchiectasis and cystic fibrosis were clearly distinguished from DPB on the basis of clinical, radiological, laboratory and genetic findings (7). The histopathologic characteristics of DPB are thickening of the respiratory bronchiolar walls with infiltration by lymphocytes, plasma cells and histiocytes, and extension of the inflammatory changes toward peribronchiolar tissues. These are useful, although not essential, for diagnosis of this condition (1, 2). We were unable to evaluate lung samples from our patients, because the specimen obtained by TBLB (case 2) was too small to represent the lung lesion, and the other two patients would not consent to a lung biopsy. In fact, it is generally difficult to carry out an open lung biopsy, which sometimes worsens the respiratory symptoms, in DPB patients, whose prognosis has now improved markedly as a result of administration of macrolide antibiotics such as erythromycin (8). Recent advances in radiological technology, i.e. HRCT, have made it possible to obtain adequate imaging information about DPB non-invasively (9). Two of our 3 patients (cases 1 and 2) underwent HRCT, which yielded findings typical of DPB, namely small nodular and branching linear lesions and bronchiectasis of medium-and small-sized bronchi. The bronchopulmonary manifestations in these RA patients were rather mild compared with those of typical DPB: in the present cases 1) fine nodular shadows were not clear in the upper lung fields and hyperinflation was mild on the chest roentgenograms, 2) the sputum volume was not as high as 50-100 ml/day, which is usually observed in a typical DPB patient (1), and 3) the extent of the FEVL0 reduction was mild and the RVs did not exceed 150% of the predicted values (cases 1 and 2). At present, the etiology and pathogenesis of DPB are not clear. Since high serum IgG and IgA levels, elevated serum CHA titers and positive RF are observed in patients with DPB, immunological factors are also thought to be involved in its pathogenesis. Therefore, the immunological disorder in RA itself and/or the effect of DMARDs on the immune system may have influenced the formation and development of DPB in RA patients, causing differences in bronchopulmonary manifestations between typical DPB and RA-associated DPB. Thus, DPB is likely to be one of the bronchopulmonary complications of RA for the following reasons: First, all of our patients (n=3) and others (n=3) with RA and DPB reported to date (10, 1 1) developed DPB after the onset ofRA. Second, to our knowledge, there have been no reports of DPB associated with connective tissue diseases other than RA, such as progressive systemic sclerosis and polymyositis/dermatomyositis. Third, an association with HLA should be considered (10). Since HLA-DR4, whose incidence is significantly higher in RA patients ( 1 2), creates a linkage disequilibrium in Japanese with HLA-B54 (13), which is strongly associated with DPB (3), it may be possible that RA and DPB are closely associated in Japanese patients.
To date few cases of RA associated with DPB have been reported, which might be due to the milder manifestations of DPB in these patients, and we propose the possibility that RA patients associated with DPB may be more common than expected in Japan. 
